AR065554A1 - Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. - Google Patents

Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.

Info

Publication number
AR065554A1
AR065554A1 ARP080100850A ARP080100850A AR065554A1 AR 065554 A1 AR065554 A1 AR 065554A1 AR P080100850 A ARP080100850 A AR P080100850A AR P080100850 A ARP080100850 A AR P080100850A AR 065554 A1 AR065554 A1 AR 065554A1
Authority
AR
Argentina
Prior art keywords
crystalline salt
pharmaceutical compositions
processes
azabiciclo
octano
Prior art date
Application number
ARP080100850A
Other languages
English (en)
Spanish (es)
Inventor
Sean M Dalziel
Miroslav Rapta
Leticia M Preza
Pierre-Jean Colson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39620376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065554(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR065554A1 publication Critical patent/AR065554A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP080100850A 2007-02-28 2008-02-28 Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. AR065554A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90409007P 2007-02-28 2007-02-28
PCT/US2008/002583 WO2008106159A1 (en) 2007-02-28 2008-02-27 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Publications (1)

Publication Number Publication Date
AR065554A1 true AR065554A1 (es) 2009-06-17

Family

ID=39620376

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100850A AR065554A1 (es) 2007-02-28 2008-02-28 Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.
ARP170102183A AR109224A2 (es) 2007-02-28 2017-07-31 Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102183A AR109224A2 (es) 2007-02-28 2017-07-31 Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento

Country Status (26)

Country Link
US (7) US7943772B2 (https=)
EP (1) EP2132204B1 (https=)
JP (2) JP5512289B2 (https=)
KR (1) KR101480530B1 (https=)
CN (1) CN101616916B (https=)
AR (2) AR065554A1 (https=)
AU (1) AU2008219615B2 (https=)
BR (1) BRPI0807974B8 (https=)
CA (1) CA2678073C (https=)
CL (1) CL2008000573A1 (https=)
CO (1) CO6220856A2 (https=)
CY (1) CY1115077T1 (https=)
DK (1) DK2132204T3 (https=)
ES (1) ES2402031T3 (https=)
HR (1) HRP20130193T1 (https=)
IL (1) IL200131A (https=)
MX (1) MX2009009141A (https=)
MY (1) MY148318A (https=)
NZ (1) NZ578871A (https=)
PL (1) PL2132204T3 (https=)
PT (1) PT2132204E (https=)
RU (1) RU2458061C2 (https=)
SI (1) SI2132204T1 (https=)
TW (1) TWI409067B (https=)
WO (1) WO2008106159A1 (https=)
ZA (1) ZA200905832B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
ATE502939T1 (de) * 2007-08-27 2011-04-15 Theravance Inc Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
EP2195313B1 (en) * 2007-08-27 2014-04-02 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CA2774021A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
HK1247105A1 (zh) 2015-04-02 2018-09-21 Theravance Biopharma R&D Ip, Llc Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US6900228B1 (en) * 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6467084B1 (en) * 1999-12-16 2002-10-15 Emware, Inc. Systems and methods for reprogramming an embedded device with program code using relocatable program code
IL151550A0 (en) 2000-03-03 2003-04-10 Ortho Mcneil Pharm Inc 3-(diarylmethylene)-8-azabicyclo [3.2.1] octane derivatives
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
EA006708B1 (ru) * 2001-10-22 2006-02-24 Пфайзер Продактс Инк. Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US7056930B2 (en) * 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
EP1615894A2 (en) * 2003-04-14 2006-01-18 Pfizer Products Inc. 3-azabicyclo 3.2.1 octane derivatives
JP2006523673A (ja) 2003-04-15 2006-10-19 ファイザー・プロダクツ・インク オピオイド受容体活性を有する３−ベンズヒドリリデン−８−アザ−ビシクロ［３．２．１］オクタン誘導体
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7435822B2 (en) 2004-02-03 2008-10-14 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo[3.2.1]octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
AU2007317788B2 (en) 2006-11-07 2013-05-02 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型

Also Published As

Publication number Publication date
US8816091B2 (en) 2014-08-26
US20080207676A1 (en) 2008-08-28
IL200131A0 (en) 2010-04-15
EP2132204A1 (en) 2009-12-16
CA2678073A1 (en) 2008-09-04
PT2132204E (pt) 2013-03-25
CA2678073C (en) 2016-01-05
KR20090115767A (ko) 2009-11-05
TW200845984A (en) 2008-12-01
SI2132204T1 (sl) 2013-05-31
US9949963B2 (en) 2018-04-24
HK1139399A1 (en) 2010-09-17
RU2458061C2 (ru) 2012-08-10
US20130072515A1 (en) 2013-03-21
CN101616916B (zh) 2011-10-12
EP2132204B1 (en) 2013-01-23
HRP20130193T1 (hr) 2013-03-31
JP5512289B2 (ja) 2014-06-04
KR101480530B1 (ko) 2015-01-08
US20110184008A1 (en) 2011-07-28
TWI409067B (zh) 2013-09-21
NZ578871A (en) 2012-01-12
JP2010520198A (ja) 2010-06-10
MX2009009141A (es) 2009-09-03
CL2008000573A1 (es) 2008-05-16
US8247555B2 (en) 2012-08-21
ZA200905832B (en) 2010-05-26
BRPI0807974B8 (pt) 2021-05-25
US20140080856A1 (en) 2014-03-20
CO6220856A2 (es) 2010-11-19
IL200131A (en) 2013-03-24
US8536335B2 (en) 2013-09-17
RU2009135834A (ru) 2011-04-10
JP2013151564A (ja) 2013-08-08
US10426766B2 (en) 2019-10-01
BRPI0807974B1 (pt) 2020-11-24
US9290491B2 (en) 2016-03-22
CN101616916A (zh) 2009-12-30
ES2402031T3 (es) 2013-04-26
AU2008219615A1 (en) 2008-09-04
US20150073014A1 (en) 2015-03-12
US20180200246A1 (en) 2018-07-19
AU2008219615B2 (en) 2013-05-09
US20160287572A1 (en) 2016-10-06
WO2008106159A1 (en) 2008-09-04
US7943772B2 (en) 2011-05-17
CY1115077T1 (el) 2016-12-14
DK2132204T3 (da) 2013-04-29
PL2132204T3 (pl) 2013-06-28
AR109224A2 (es) 2018-11-07
MY148318A (en) 2013-03-29
BRPI0807974A2 (pt) 2014-09-16

Similar Documents

Publication Publication Date Title
AR065554A1 (es) Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
AR087208A2 (es) FORMA CRISTALINA DE 1-CLORO-4-(b-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO, UN METODO PARA SU PREPARACION Y EL USO DEL MISMO PARA PREPARAR MEDICAMENTOS
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
PE20121179A1 (es) Forma cristalina de hemifumarato de alisquireno
AR082804A1 (es) Formas cristalinas de un inhibidor del factor xa
CR20150401A (es) Formas de rifaximina y sus usos
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
BR112013009117A2 (pt) sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
AR077203A1 (es) Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms)
CR20120620A (es) Nuevas formas de rifaximina y usos de las mismas
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
PY09020965A (es) &#34;Preparación de relajante de músculo esquelético en formas de dosificación de liberación controlada&#34;.
ECSP045484A (es) Derivados de carbamato de quinuclidina
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
BRPI0912267A2 (pt) sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
BRPI0914912A2 (pt) processo para a preparação de um composto, e de um inibidor de mtor quinase, sal de fumarato, composição farmacêutica, uso de um sal de fumarato, e, métodos para produzir um efeito inibitório mtor, e para produzir um efeito anti-câncer em um animal de sangue quente
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
BRPI0516003A (pt) composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos
CL2009001137A1 (es) Compuestos derivados de cicloheptanocarboniloxi-1-azonia-biciclo[2.2.2]-octano, moduladores de receptores muscarinicos; composiciones farmaceuticas; proceso de preparacion de dicha composicion; y uso en el tratamiento de una enfermedad pulmonar obstructiva cronica.

Legal Events

Date Code Title Description
FC Refusal